Group 1 - The core point of the article is that Lianhong Xinke (SZ 003022) held its eighth board meeting on December 5, 2025, to discuss the proposal for conducting hedging business in 2026 [1] - For the first half of 2025, Lianhong Xinke's revenue composition was as follows: advanced polymer materials accounted for 56.7%, specialty fine materials accounted for 23.35%, and by-products and others accounted for 19.95% [1] - As of the report date, Lianhong Xinke's market capitalization was 25.6 billion yuan [1]

Core Viewpoint - The company is focusing on biodegradable materials as a key strategic development direction, with plans to increase capital for its subsidiary to enhance its financial structure [1] Group 1: Company Strategy - The company announced a capital increase of 150 million yuan to its subsidiary, Jiangxi Academy of Biological New Materials Co., Ltd. [1] - The subsidiary primarily engages in the research, production, and sales of lactic acid and polylactic acid [1] - Other shareholders of the subsidiary will not participate in this capital increase [1]

Core Viewpoint - The company is focusing on biodegradable materials as a key strategic development direction, with plans to enhance its subsidiary's financial structure through a capital increase [1] Group 1: Company Strategy - The company plans to invest 150 million yuan in its subsidiary, Jiangxi Academy of Biological New Materials Co., Ltd., to accelerate strategic layout and development [1] - The capital increase aims to supplement the working capital of the subsidiary and improve its asset-liability structure [1] Group 2: Subsidiary Operations - Jiangxi Academy of Biological New Materials Co., Ltd. is primarily engaged in the research, production, and sales of lactic acid and polylactic acid [1] - Other shareholders of the subsidiary will not participate in this capital increase [1]

联泓新科（003022）(003022.SZ)发布公告，为积极响应国家科技创新政策导向，落实公司创新驱动发 展战略，加大科技创新投入力度，同时进一步拓宽融资渠道，降低融资成本，优化债务结构，公司拟向 中国银行间市场交易商协会申请注册发行最高不超过人民币10亿元(含10亿元)科技创新债券。 ...

智通财经APP讯，联泓新科(003022.SZ)发布公告，为积极响应国家科技创新政策导向，落实公司创新驱 动发展战略，加大科技创新投入力度，同时进一步拓宽融资渠道，降低融资成本，优化债务结构，公司 拟向中国银行间市场交易商协会申请注册发行最高不超过人民币10亿元(含10亿元)科技创新债券。 ...

Core Viewpoint - The company is focusing on biodegradable materials as a key strategic development direction, with plans to increase capital for its subsidiary to enhance its financial structure and support growth [1] Group 1: Company Strategy - The company intends to invest 150 million yuan in its subsidiary, Jiangxi Academy of Biological New Materials Co., Ltd. (referred to as "Academy Biology"), to accelerate its strategic layout and development [1] - The investment aims to supplement the working capital of Academy Biology and improve its asset-liability structure [1] Group 2: Subsidiary Operations - Academy Biology primarily engages in the research, production, and sales of lactic acid and polylactic acid [1] - The other shareholders of Academy Biology will not participate in this capital increase [1]

Group 1 - The core focus of the company is on biodegradable materials, with a strategic emphasis on the research, production, and sales of lactic acid and polylactic acid through its subsidiary, Jiangxi Academy of Biological New Materials Co., Ltd [1] - The company plans to increase its investment in Jiangxi Academy by 150 million yuan to enhance its strategic layout and improve its asset-liability structure, with other shareholders not participating in this round of funding [1] - As of January to June 2025, the company's revenue composition is as follows: advanced polymer materials account for 56.7%, specialty fine materials account for 23.35%, and by-products and others account for 19.95% [1] Group 2 - The current market capitalization of the company is 25.6 billion yuan [1]

联泓新科公告称，为加快战略布局，公司拟以自有资金1.5亿元向控股子公司科院生物增资，其他股东 不同步增资。本次交易构成关联交易，不构成重大资产重组。科院生物2024年营收483.60万元、净利 润-222.96万元，2025年前三季度营收5289.66万元、净利润1576.72万元。增资后，公司持股比例将由 51%增至65.7%。公司应在协议签署20个工作日内付款，科院生物在收款20个工作日内完成工商变更。 ...

证券代码：003022 证券简称：联泓新科 公告编号：2025-052 联泓新材料科技股份有限公司 关于 2026 年度使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 联泓新材料科技股份有限公司（以下简称"公司"）于 2025 年 12 月 5 日召开 第三届董事会第八次会议，审议通过《关于 2026 年度使用闲置自有资金进行现金 管理的议案》，同意公司及子公司使用额度不超过人民币 10 亿元闲置自有资金进 行现金管理，期限为 2026 年 1 月 1 日至 2026 年 12 月 31 日。在上述额度和期限 范围内，资金可循环使用。 本次使用闲置自有资金进行现金管理事项在公司董事会的审批权限范围内， 无需提交股东会审议，不构成关联交易。公司董事会审议通过后，由经营层在上 述额度范围内行使相关决策权、签署相关合同文件。具体情况如下： 一、使用闲置自有资金进行现金管理的概述 （一）目的 为提高自有资金的使用效率，公司及子公司在确保资金安全的前提下，合理 利用部分闲置自有资金进行现金管理，可以增加资金收益，更好地实现公司资金 的 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：003022 证券简称：联泓新科 公告编号：2025-053 联泓新材料科技股份有限公司 关于向控股子公司增资的公告 鉴于科院生物股东九江泓盛锦企业管理合伙企业（有限合伙）（以下简称"九 江泓盛锦"）有限合伙人含公司部分董事、高级管理人员，根据有关法律法规及 监管规则的规定，本次交易构成关联交易。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组， 不构成重组上市。 2、审议程序 公司于 2025 年 12 月 5 日召开第三届董事会第八次会议，审议通过了《关于 向控股子公司江西科院生物新材料有限公司增资的议案》，关联董事回避表决。 上述交易已经公司第三届董事会第三次独立董事专门会议审议通过。 一、本次交易概述 1、本次交易基本情况 生物可降解材料是联泓新材料科技股份有限公司（以下简称"公司"）战略 发展的重点方向之一，公司控股子公司江西科院生物新材料有限公司（下称"科 院生物"或"标的公司"）主要从事乳酸、聚乳酸的研发、生产与销售。为加快 公司战略布局及发展，补充科院生物流动资金，改善 ...